Salud financiera de hoja de balance de Amplia Therapeutics

Salud financiera controles de criterios 5/6

Amplia Therapeutics tiene un patrimonio de los accionistas total de A$11.4M y una deuda total de A$1.5M, lo que sitúa su ratio deuda-patrimonio en 13.1%. Sus activos y pasivos totales son A$14.8M y A$3.4M respectivamente.

Información clave

13.1%

Ratio deuda-patrimonio

AU$1.49m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$3.39m
Patrimonio	AU$11.42m
Total pasivo	AU$3.43m
Activos totales	AU$14.85m

Actualizaciones recientes sobre salud financiera

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Jan 13

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Apr 28

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Jan 06

Recent updates

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Jan 13

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Apr 28

Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings

Feb 28

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Jan 06

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$6.8M) de ATX superan a sus pasivos a corto plazo (A$3.4M).

Pasivo a largo plazo: Los activos a corto plazo de ATX (A$6.8M) superan a sus pasivos a largo plazo (A$23.4K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: ATX tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de ATX ha crecido de 0% a 13.1% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ATX tiene suficiente cash runway para 8 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que ATX disponga de suficiente cash runway para 8 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Amplia Therapeutics

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Amplia Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Recent updates

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.9 million.

Amplia Therapeutics Limited, Annual General Meeting, Aug 23, 2024

New minor risk - Shareholder dilution

Amplia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.27 million.

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.27 million.

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.27 million.

New major risk - Market cap size

Amplia Therapeutics Limited Announces FDA Clearance of it's IND for Pancreatic Cancer Trial in US

New major risk - Financial position

New major risk - Market cap size

Amplia Therapeutics Limited Announces Chief Financial Officer Changes

New major risk - Market cap size

New major risk - Market cap size

Amplia Therapeutics Limited, Annual General Meeting, Aug 24, 2023

Amplia Receives Grant to Collaborate with CSIRO

Amplia Therapeutics Limited Announces Dose Escalation Approved in ACCENT Clinical Trial of AMP945

Amplia Therapeutics Limited Appoints Christopher Burns as Managing Director, Effective December 5, 2022

Amplia Therapeutics Limited Announces CEO Changes

Amplia Therapeutics Limited Announces First Patient Recruited to ACCENT Trial in Pancreatic Cancer

Amplia Therapeutics Limited, Annual General Meeting, Aug 25, 2022

Amplia Therapeutics Limited Shows AMP945 Efficacy in Model of Lung Fibrosis

Amplia Therapeutics Limited Receives Second Ethics Clearance for Phase 2 Trial

Amplia Therapeutics Limited Receives Human Research Ethics Committee Approval to Initiate Phase 2 Clinical Trial of Its Focal Adhesion Kinase Inhibitor, AMP945

Amplia Therapeutics Limited Completes Manufacture of AMP945 for Planned Trials

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Non-Executive Director recently bought AU$104k worth of stock

Chief Financial Officer Jeff Carter has left the company

Amplia to Conduct Phase 2 Trial in First-Line Pancreatic Cancer Patients

Non-Executive Director recently bought AU$122k worth of stock

Amplia Therapeutics Limited Announces Results from Successful Phase 1 Clinical Trial of Amp945

Amplia Therapeutics Limited Receives New Data from its Collaboration with Professor Paul Timpson of the Garvan Institute of Medical Research, Sydney

Amplia Therapeutics Limited announced that it expects to receive AUD 3.81455 million in funding from Platinum Investment Management Limited, Blueflag Holdings Pty Ltd, Acorn Capital Limited, and other investors

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Amplia Therapeutics Limited Completes Single Dose Study of AMP945

Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings

Amplia Therapeutics Limited Initiates Multiple Dose Study of AMP945

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

New 90-day high: AU$0.22

Amplia Therapeutics Limited Announces First Human Dose in Phase 1 Clinical Trial of AMP945

Amplia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 3.987791 million.

Amplia Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera